Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: Toward routine preoperative dosage of Von Willebrand factor?

Fiche publication

Date publication

février 2017

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GROSS Isabelle , Pr ROHR Serge , Dr ROMAIN Benoit , Pr BRIGAND Cécile

Tous les auteurs :
Delhorme JB, Sattler L, Severac F, Triki E, Gross I, Romain B, Rohr S, Grunebaum L, Brigand C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28209329

Résumé

Oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC-ox) induces specific morbidity with hemorrhagic complications (HC). The aim of this study was to identify preoperative, intraoperative and postoperative HC predictive factors after HIPEC-ox.